tiprankstipranks
Company Announcements

Photocure’s Hexvix Gains Approval in China

Photocure’s Hexvix Gains Approval in China

Photocure ASA (PHCUF) has released an update.

Discover the Best Stocks and Maximize Your Portfolio:

Photocure ASA’s partner, Asieris Pharmaceuticals, has received marketing authorization for Hexvix in China, a drug used for enhanced detection of bladder cancer during cystoscopy. This approval marks a significant step for Photocure in expanding its presence in the Asian market, potentially impacting the company’s growth and stock value positively.

For further insights into PHCUF stock, check out TipRanks’ Stock Analysis page.

Related Articles
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1